Posted on

cbd gummies corona

CBD might one day prove to be helpful for people who have or who are recovering from a viral illness, but the current data don’t support its use with the coronavirus, says Jahan Marcu, PhD, a longtime cannabis researcher in New York City and editor in chief of the American Journal of Endocannibinoid Medicine.

But this doesn’t mean it’s effective against the novel coronavirus. And for people who take certain medications, it may not be safe.

A Look at the Evidence (0r Lack Thereof)

One giveaway a product isn’t up to snuff: It’s too cheap. Good CBD is costly, with a bottle of tincture typically selling for $60 or more.

The chemical is not side-effect free, with people taking CBD reporting problems including diarrhea, fatigue, and vomiting, according to a 2019 review in Current Neuropharmacology.

There is no evidence that CBD can stave off or treat COVID-19 — and for people who take certain medications, it may even cause harm.

Onaivi ES, Green MR, Martin BR. Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 1990;253(3):1002-9. View abstract.

Carlini EA, Cunha JM. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol 1981;21(8-9 Suppl):417S-27S. View abstract.

Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet Syndrome. N Engl J Med. 2017 May 25;376(21):2011-2020. View abstract.

Special Precautions and Warnings

Nitecka-Buchta A, Nowak-Wachol A, Wachol K, et al. Myorelaxant Effect of Transdermal Cannabidiol Application in Patients with TMD: A Randomized, Double-Blind Trial. J Clin Med. 2019 Nov 6;8(11). pii: E1886. View abstract.

Iuvone T, Esposito G, De Filippis D, et al. Cannabidiol: a promising new drug for neurodegenerative disorders? CNS Neurosci Ther 2009;15(1):65-75. View abstract.

Carroll CB, Bain PG, Teare L, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 2004;63(7):1245-50. View abstract.

Yamaori S, Kushihara M, Yamamoto I, Watanabe K. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective potent inhibitors of human CYP1 enzymes. Biochem Pharmacol 2010;79(11):1691-8. View abstract.